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Abstract 
Derivatives of the standard cationic photosensitiser, methylene blue, were synthesised, 
having extra amino (basic) functionality in the auxochromic side-chain.  The resulting 
analogues were profiled for photodynamic activity in vitro, and screened against standard 
Gram-positive and Gram-negative bacteria for photobactericidal activity.  The substitution 
pattern of the derivatives was such that ionisation of the amino groups in situ, via 
protonation, provided a range of charge distribution and degree of charge across the 
molecular framework. 
While most examples exhibited greater activity than the lead compound, in addition to 
similar activity to the known, but more powerful, phenothiazinium photoantimicrobial, 
dimethyl methylene blue, this was also associated with relatively high dark toxicity, inferring 
that these compounds were targeting crucial structures before illumination. 
One derivative having an asymmetrical structure, with separation between a lipophilic and a 
hydrophilic region exhibited a combination of very high phototoxicity coupled with very low 
dark effects, against both the standard screen and an additional one containing further, 
relevant pathogen species, including Candida albicans.  It is suggested that the great activity 
of this analogue is due to efficient membrane targeting. 
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1. Introduction 
 
The phenothiazinium salt methylene blue (Figure 1) has considerable antiquity among dyes 
used in biology and medicine, having featured in the vanguard of colorants for microscopy 
in the late 19th Century.  It was also a lead compound in the work of Koch, Ehrlich and others 
in their development of the theory of selective toxicity and, subsequently, of modern 
chemotherapy [1]. 
 
Methylene blue was used by Guttmann and Ehrlich in the clinical cure of falciparum malaria 
in 1891 [2], and this became the basis of antimalarial research later carried out at IG Farben 
in the immediate aftermath of the First World War. 
 
 
 
 
Figure 1.  Methylene blue and early antimalarial drugs 
 
Among derivatives of the lead compound was a group of methylene blue analogues having 
alterations in one of the dimethylamino auxochromes, a constituent methyl group being 
extended in length and terminated with another amine (Figure 1).  The resulting 
aminoalkylamino chain, and its elaborations, was found to increase antimalarial activity in 
the canary model developed by Ernst Roehl [3].  Further testing led to the development of 
Paludenblau (Figure 1) although this was eventually discontinued in the face of less staining 
antimalarials such as the acridine mepacrine and the quinoline chloroquine (Figure 1) [4]. 
 
In related work based on the acridine chromophore, it was found that the size of the side 
chain was influential on the type of activity observed, longer aminoalkylamino moieties 
being associated with antiplasmodial activity, whereas simpler alkylamino- or amino groups 
endowed compounds useful against bacteria (e.g. proflavine, aminacrine) [5].  In addition, 
the combination of a planar chromophore and an aminoalkylamino side chain has been used 
more recently to target nucleic acid, both in anticancer and antiviral applications [6]. 
 
As part of an ongoing photosensitiser discovery programme, novel photoantimicrobial 
compounds have been sought, based on the phenothiazinium chromophore and, indeed, 
using methylene blue as a lead structure.  While the low human toxicity of this compound is 
evidenced by its use on a daily basis in healthcare concerns around the world, it remains a 
relatively weak photoantimicrobial per se. 
 
Since the analogues of methylene blue produced by IG Farben, including methylene blue 
itself, were realised via traditional (i.e. dye industry) synthetic routes from the requisite p-
phenylenediamine/aniline derivatives, the range of compounds available was relatively 
small due to the strong oxidising agents employed, such as acidic dichromate, which would 
also denature less robust groups in the reactants.  In addition, the aqueous reaction media 
employed presented solubility difficulties with e.g. higher alkyl or halogenated derivatives. 
 
In terms of expanding the range of derivatives available for screening as photosensitisers, 
the replacement of chromium(VI) with weaker oxidants such as silver(I) and the use of 
methanol as a reaction solvent represent a positive move, particularly in producing ring-
substituted derivatives [7].  Similarly, synthesis of derivatives from 10H-phenothiazine has 
expanded the range of auxochromic groups enormously [8-10], especially since this allows 
facile production of asymmetrically-substituted derivatives. 
 
The current work covers the synthesis of asymmetrical and symmetrical phenothiazinium 
derivatives having additional amino functionality in one or both auxochromic groups and 
the screening of these compounds against bacteria and fungi [11]. 
 
  
2. Materials and Methods 
 
10H-Phenothiazine, bromine, iodine, all amines and silica gel were obtained from Sigma 
Aldrich (UK).  Solvents were obtained from Fischer UK.  Spectrophotometric measurements 
were carried out using a Hewlett Packard 8452A diode array spectrophotometer.  Accurate 
molecular ion masses for the derivatives were obtained using a Micromass LCT-TOF mass 
spectrometer. 
 
2.1 Symmetrical photosensitisers, general route 
 
3,7-Dibromophenothiazinium bromide 
 
10H-Phenothiazine (2 g, 10 mmol) was dissolved in 150 mLof glacial acetic acid at room 
temperature.  Bromine (10 mL, mmol) was added in one amount and the reaction stirred 
vigorously for one minute.  Water (400 mL) was then added in one amount, producing a red-
brown solution and a red-black amorphous solid, isolated by filtration at the pump.  The 
solid was washed with water and then with ether until the washings were colourless.  The 
resulting dark red solid was powdered and dried in vacuo at room temperature to constant 
weight, yield = 4.96 g, 84%. 
 
The alkylaminoalkylamino compound (15 mmol) was dissolved in dichloromethane (100 mL) 
at room temperature, and solid 3,6-dibromophenothiazinium tribromide (1.00g, 1.7 mmol) 
was added in one amount.  The resulting green-blue solution was stirred at room 
temperature for a further two hours at room temperature.  Product isolation was achieved 
by aqueous washing of the reaction mixture, drying and concentration of the resulting 
organic solution and precipitation with dry ether.  Further purification by column 
chromatography, (SiO2 / CH2Cl2, CH3OH), was carried out where necessary. 
 
3,7-Bis(bis(3-(dimethylamino)propyl)amino)phenothiazinium bromide (1a) 
 
 
 
From bis(3-(dimethylaminopropyl)amine, as a blue black solid, yield = 228 mg, 21 %; HRMS 
(ESI) calcd for C32H54N7S requires 568.42, found 568.40; max (MeOH) 668 nm. 
 
3,7-Bis(bis(3-(diethylamino)propyl)amino)phenothiazinium bromide (1b) 
 
 
 
From bis(2-(diethylamino)ethyl)amine, as a blue black solid, yield = 396 mg, 31 %; HRMS 
(ESI) calcd for C36H62N7S requires 624.48, found 624.49; max (MeOH) 667 nm. 
 
3,7-Bis((2-(dimethylamino)ethyl)(ethyl)amino)phenothiazinium bromide (1c) 
 
 
 
From (2-(dimethylamino)ethyl)ethylamine as a blue black solid, yield = 187 mg, 22 %; HRMS 
(ESI) calcd for C28H44N5S requires 426.27, found 426.28; max (MeOH) 662 nm. 
 
 
 
2.2 Asymmetric photosensitisers, general route 
 
Phenothiazinium tetraiodide 
 
10H-Phenothiazine (2 g, 10 mmol) was dissolved in 50 mL of dichloromethane at room 
temperature.  A solution of iodine (8 g, 32 mmol) in dichloromethane (150 mL) was added, 
and the whole stirred for three hours at room temperature.  The resulting purple-black solid 
was filtered at the pump, washed free of iodine with dichloromethane, powdered and dried 
to constant weight.  Yield of black powder = 6.05 g, 86%. 
 
 
3-Dialkylaminophenothiazinium triiodides 
 
Phenothiazinium tetraiodide (2.15 g, mmol) was dissolved in methanol (20 mL) at room 
temperature and a solution of dialkylamine (7.6 mmol) in methanol (20 mL) added dropwise 
over 20 minutes.  The reaction was allowed to stir at room temperature for a further three 
hours, monitored by thin layer chromatography (SiO2 / 3% aqueous NH4OAc in CH3OH).  The 
solution was allowed to stand overnight and the resulting black solid filtered off and washed 
with cold methanol. 
 
3-Dialkylamino-7-dialkylaminoalkylaminophenothiazinium iodides 
 
To a suspension of 3-dialkylaminophenothiazinium triiodide (0.75 mmol) in methanol (10 
mL) was added dropwise the requisite dialkylaminoalkylamine (1.8 mmol) in 10 mL 
methanol.  The reaction was allowed to stir at room temperature for 3 hours and then to 
stand overnight.  The resulting black solid was filtered at the pump, dried and then 
recrystallised from the minimum of methanol.  Several examples required further 
purification by column chromatography, (SiO2 / CH2Cl2, CH3OH). 
 
 
3-(Di-n-hexylamino)-7-((2-(diethylamino)ethyl)(ethyl)amino)phenothiazinium iodide (2a) 
 
 
 
From 3-di-n-hexylaminophenothiazinium triiodide and (2-(diethylamino)ethyl)ethylamine as 
a black solid, yield = 171 mg, 35 %; HRMS (ESI) calcd for C32H51N4S requires 523.38, found 
523.38; max (MeOH) 660 nm. 
 
 
3-(Di-n-butylamino)-7-((2-(diethylamino)ethyl)(ethyl)amino)phenothiazinium iodide (2b) 
 
 
 
From 3-diethylaminophenothiazinium triiodide and (2-(dimethylamino)ethyl)ethylamine as 
a black solid, yield = 129 mg, 29 %; HRMS (ESI) calcd for C28H43N4S requires 467.32, found 
467.28; max (MeOH) 665 nm. 
 
 
3-(Diethylamino)-7-((2-(diethylamino)ethyl)(methyl)amino)phenothiazinium iodide (2c) 
 
 
 
From 3-diethylaminophenothiazinium triiodide and (2-(diethylamino)ethyl)methylamine as 
a black solid, yield = 102 mg, 26 %; HRMS (ESI) calcd for C23H33N4S requires 397.24, found 
397.20; max (MeOH) 652 nm. 
 
 
3-(Bis(3-(dimethylamino)propyl)amino)-7-(di-n-propylamino)phenothiazinium iodide (2d) 
 
 
 
From 3-di-n-propylaminophenothiazinium triiodide and bis(3-(dimethylaminopropyl)amine 
as a black solid, yield = 151 mg, 33 %; HRMS (ESI) calcd for C28H44N5S requires 482.33, found 
482.29; max (MeOH) 661 nm. 
 
 
 
2.3 Singlet oxygen production 
 
Singlet oxygen production by the photosensitisers was assayed using the decolourisation of 
2,3,4,5-tetraphenylcyclopentadienone (TPCPD) in dichloromethane.  Thus the decrease in 
absorption at 500 nm was monitored spectrophotometrically with time as in the method of 
Cincotta et al. [12].  The singlet oxygen yield for the standard photosensitiser, methylene 
blue (MB) is given as 0.443 [13].  By assuming that the decrease in absorption of TPCPD at 
500 nm is directly proportional to its reaction with singlet oxygen, the time for a 50% 
decrease in absorption caused by each of the derivatives under identical conditions (t½Der) 
thus gives a measure of its photosensitising efficiency.  Thus, the time for the TPCPD 
absorption to decrease by 50% due to MB photosensitisation (t½MB) was taken as 1.0.  To 
calculate the singlet oxygen yield for the derivatives (Der), the following formula was used: 
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2.3 Hydrophilic-lipophilic balance (LogP) 
 
The lipophilicities of the photosensitisers were calculated in terms of log P, the logarithm of 
their partition coefficients between phosphate-buffered saline and 1-octanol.  The data 
were calculated using the standard spectrophotometric method [13] based on the 
relationship: 
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where A and A1 are the absorption intensities before and after partitioning respectively and 
Vw and Vo are the respective volumes of the aqueous and 1-octanol phases. Determinations 
were repeated three times. 
 
 
2.4 Antibacterial Screening 
The photobactericidal efficacies of the derivatives in addition to that of the known 
photosensitiser methylene blue were measured against a Gram positive and a Gram 
negative organism, Staphylococcus aureus (NCTC 6571) and Escherichia coli (NCTC 10418) 
respectively.  Both strains were grown in Mueller-Hinton Broth and then diluted to a 
concentration of 106 colony-forming units/mL.  Aliquots of the strains were then incubated 
for 1 hour at 37 C in microtitre trays with various concentrations of photosensitiser in a 
range of from 100 to 3 M, with zero photosensitiser concentrations in each case for control 
purposes.  The trays were then either illuminated for twenty minutes using an array of light-
emitting diodes (660 nm) giving a light dose of 6.2 J cm-2 or alternatively foil-covered to 
provide dark controls.  From each well showing an inhibition of growth of the micro-
organism, 1 l was sub-cultured on nutrient agar, using the Miles-Misra method, and 
incubated for 18 hours at 37 C.  The minimum bactericidal concentrations were then 
determined as the lowest concentration for each photosensitiser giving no bacterial growth. 
The candidate compound performing best in this initial screen (2d) was then tested further 
against the following clinically relevant organisms: Enterococcus faecalis (NCIMB 13280), 
Proteus mirabilis (NCIMB 5887) and a clinical strain of Klebsiella pneumoniae (isolated at the 
Clatterbridge Hospital, UK), using the same culture methodology.  Antifungal screening was 
carried out similarly against the yeast Candida albicans (NCPF 8179), using Sabouraud broth 
and agar. 
 
  
3. Results and Discussion 
 
3.1 Photosensitisers 
A series of phenothiazinium derivatives having dialkylamino-type substitution was produced 
as expected, the maximum wavelength of absorption in aqueous media being in line with 
that of previous series of methylene blue analogues, in the region of 660-670 nm [14-16].  
This is simply explained, given the reactivity of the secondary amino function present in the 
diamines and triamines employed in the syntheses, i.e. the resulting products were, 
effectively,3,7-bis(dialkylamino)phenothiazinium derivatives, similar to methylene blue.  
Pure compound yields were low (20-30%), again in line with previous work employing 
halogen oxidation protocols [14-16].  Attempts to extend the series utilising primary 
alkylamino reactants were unsuccessful using the same protocols (data not included), the 
reactants being recovered unchanged. Each of the products reported was purified by 
column chromatography on silica gel. 
The compounds examined in the present study may be broadly classified via substitution 
pattern and degree.  Thus the derivatives might be symmetrically or unsymmetrically 
substituted with respect to both auxochromic moieties and each of these groups might be 
abasic, mono- or dibasic, depending on the number of amino termini so possessed.  While 
all of the compounds are at least permanently monocationic due to the delocalised 
chromophoric charge (i.e. as for methylene blue), the basicity of the free tertiary amino 
moieties in the various side chains means that additional, though localised, cationic sites 
would be formed by ionisation (N-protonation) in aqueous media.  Thus compounds 2a-c 
might be considered as dicationic, compounds 1c and 2d tricationic and compounds 1a and 
1b pentacationic (e.g. Figure 2). 
 
 
 
 
Figure 2.  Polycationic forms of the derivatives. 
 
All of the derivatives produced singlet oxygen in the standard spectrophotometric 
cyclopentadienone oxidation screen (Table 1), although, unsurprisingly, in vitro yields did 
not correlate with data resulting from the antimicrobial screening.  Generally the derivatives 
exhibited increased lipophilicities (i.e. more positive Log P values compared to the parent 
compound, methylene blue, Table 1), which were generally concomitant with increased 
hydrocarbon content in the auxochromic function, while the presence of the maximum four 
ionisable dialkylamino termini (e.g. compound 1b, Log P +0.11 ) provided the most 
hydrophilic examples of the current series. 
 
  
Compound max (nm, MeOH) Log P Relative yield of 
singlet oxygen 
MB 656 -0.10 1.0 
1a 668 +0.21 0.6 
1b 667 +0.11 0.3 
1c 662 +0.76 0.2 
2a 660 +1.25 0.4 
2b 665 +1.09 0.3 
2c 652 +0.74 1.4 
2d 661 +0.57 0.2 
DMMB 648 +1.11 1.2 
 
Table 1.  Measured physicochemical and photoproperties for the new photosensitisers and 
comparators employed in the study 
 
3.1 Antimicrobial efficacy 
As noted above, although it is used in several clinical photodynamic protocols, methylene 
blue is not an ideal photoantimicrobial candidate. While the relatively high MBC values 
exhibited against Staphylococcus aureus (Gram-positive) and Escherichia coli (Gram-
negative) (Figure 3) are offset by a known lack of human toxicity, its dark/light differential is 
also low.  Most of the compounds tested in the current study were much more efficient 
than the parent compound in cell killing. The known analogue dimethyl methylene blue was 
included as an established, more powerful photosensitiser. 
 
 
 
 
Figure 3.  Photobactericidal data for methylene blue, dimethyl methylene blue (DMMB) and 
the derivatives.  MBC = minimum bactericidal concentration giving total bacterial kill. Key: 
activity against Staphylococcus aureus, pale grey (+ light), black (dark); activity against 
Escherichia coli, white (+ light), dark grey (dark). 
 
Among the synthesised series of analogues, noticeably, the established antimalarial 
derivative, paludenblau (2c), was a weak photobactericidal agent, similar to methylene blue 
as suggested above, despite being the most efficient producer of singlet oxygen in the 
spectrophotometric assay (Table 1).  This suggests a lack of uptake and/or interaction with 
the bacterial target.  However, asymmetrical compounds of similar pattern but having 
greater alkyl content were highly effective against both Gram-types used in the initial screen 
(Figure 3), although with variable dark toxicities, indeed having similar dark:light ratios to 
those of methylene blue and dimethyl methylene blue. 
Conversely, compound 2d exhibited the lowest minimum photobactericidal concentration (≤ 
3.125 M) combined with the highest dark toxicity (≥ 100 M) in the standard antibacterial 
screen.  Given this activity, it was then tested against three further relevant bacterial strains 
and the yeast, Candida albicans.  It should be noticed that two of the bacterial strains, 
Klebsiella pneumoniae and Enterococcus faecalis, have particular clinical significance in 
terms of their common involvement in conventional-resistant infectious disease, such as 
hospital-acquired pneumonia and urinary tract infections, respectively [17,18]. Compound 
2d was highly active against each of these follow-on strains (e.g. MBC vs. E. faecalis = 0.19 
M), and again exhibited no measurable dark toxicity (Table 2).  It is emphasised that 2d 
exhibited excellent photoantimicrobial activity, given the similar high efficacy exhibited 
against the yeast challenge. 
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  E. faecalis  P. mirabilis  K. pneumoniae  C. albicans  
 Light Dark Light Dark Light Dark Light Dark 
2a 0.19 100 0.39 100 3.13 100 3.13 100 
 
Table 2.  Antimicrobial activity for compound 2d.  Minimum antimicrobial concentration (in 
M) giving total kill.  
 
In terms of the ionisation pattern discussed above, compound 2d, being potentially 
tricationic (Figure 2), exhibits one which has been shown to be active by several groups 
[19,20].  Thus the molecule has recognisable lipophilic and hydrophilic regions which may 
aid in orientation in membranous regions in the microbial cell.  The tricationic example 1c 
has a different (symmetrical) distribution of positive charge, as is the case also for the 
potentially pentacations formed by compounds 1a and 1b (Figure 2).  The lower dark:light 
toxicity ratio for these derivatives suggests that – if the target is a membrane – they are 
more generally destructive in terms of membrane structural integrity, whereas compound 
2d causes much greater damage, but only on illumination, across the range of microbial 
targets. 
 
4. Conclusion 
A range of new derivatives of methylene blue, having basic functionality in the side chain, 
have been synthesised and tested.  The presence of functional groups other than hydroxyl 
(HO-) is relatively unusual in phenothiazinium derivatives.  While most of the series were, as 
expected, more active than the parent compound, methylene blue, several of the new 
analogues were also more active than dimethyl methylene blue, a powerful photosensitiser 
which has been suggested as a replacement for methylene blue itself in clinical contexts 
[21], but which should not be employed due to the high mammalian toxicity reported from 
in vitro studies [22].  The large differential dark:light toxicity shown by the asymmetric 
compound 2d throughout the current study is most encouraging in this respect, but this will 
obviously require further testing/analogue comparison to allow significant further progress. 
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